BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E
157 results:

  • 1. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
    Bazinet A; Kantarjian H; Bataller A; Pemmaraju N; Borthakur G; Chien K; Alvarado Y; Bose P; Jabbour E; Yilmaz M; DiNardo C; Issa G; Montalban-Bravo G; Short N; Sasaki K; Bull-Linderman D; Daver N; Garcia-Manero G; Ravandi F; Kadia T
    Lancet Haematol; 2024 Apr; 11(4):e287-e298. PubMed ID: 38548404
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Influence of different pH milieu on the structure and function of human Aurora kinase B protein (AURK-B): Amalgamation of both spectroscopic and computational approach.
    Gupta D; Kumari R; Kumar M; Singh M; Rawat S; Ethayathulla AS; Kaur P
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 May; 312():124047. PubMed ID: 38394881
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The novel miR-873-5p-ywhae-PI3K/AKT axis is involved in non-small cell lung cancer progression and chemoresistance by mediating autophagy.
    Li Z; Liu J; Wang P; Zhang B; He G; Yang L
    Funct Integr Genomics; 2024 Feb; 24(2):33. PubMed ID: 38363382
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
    Bataller A; Montalban-Bravo G; Bazinet A; Alvarado Y; Chien K; Venugopal S; Ishizawa J; Hammond D; Swaminathan M; Sasaki K; Issa GC; Short NJ; Masarova L; Daver NG; Kadia TM; Colla S; Qiao W; Huang X; Kanagal-Shamanna R; Hendrickson S; Ravandi F; Jabbour E; Kantarjian H; Garcia-Manero G
    Lancet Haematol; 2024 Mar; 11(3):e186-e195. PubMed ID: 38316133
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Decision aids for people facing health treatment or screening decisions.
    Stacey D; Lewis KB; Smith M; Carley M; Volk R; Douglas EE; Pacheco-Brousseau L; Finderup J; Gunderson J; Barry MJ; Bennett CL; Bravo P; Steffensen K; Gogovor A; Graham ID; Kelly SE; Légaré F; Sondergaard H; Thomson R; Trenaman L; Trevena L
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD001431. PubMed ID: 38284415
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
    Sobas M; Knopinska-Posluszny W; Piątkowska-Jakubas B; García-Álvarez F; Díez MEA; Caballero M; Martínez-Cuadrón D; Aguiar E; González-Campos J; Garrido A; Algarra L; Salamero O; de la Serna J; Sayas MJ; Perez-Encinas MM; Vives S; Vidriales B; Labrador J; Prado AI; Celebrin L; Mayer J; Brioso J; de Laiglesia A; Bergua JM; Amigo ML; Rodriguez-Medina C; Polo M; Pluta A; Cichocka E; Skarupski M; Sanz MA; Wierzbowska A; Montesinos P
    Ann Hematol; 2024 Feb; 103(2):451-461. PubMed ID: 38110588
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
    Montalban-Bravo G; Jabbour E; Borthakur G; Kadia T; Ravandi F; Chien K; Pemmaraju N; Hammond D; Dong XQ; Huang X; Schneider H; John R; Kanagal-Shamana R; Loghavi S; Kantarjian H; Garcia-Manero G
    Br J Haematol; 2024 Mar; 204(3):898-909. PubMed ID: 37946611
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Repurposing of Strychnine as the Potential Inhibitors of Aldo-keto Reductase Family 1 Members B1 and B10: Computational Modeling and Pharmacokinetic Analysis.
    Sarfraz M; Aziz M; Afzal S; Channar PA; Alsfouk BA; Kandhro GA; Hassan S; Sultan A; Hamad A; Arafat M; Qaiser MN; Ahmed A; Siddique F; Ejaz SA
    Protein J; 2024 Apr; 43(2):207-224. PubMed ID: 37940790
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (mds): A state-of-the-art report on behalf of the International Consortium for mds (icmds).
    Stahl M; Bewersdorf JP; Xie Z; Porta MGD; Komrokji R; Xu ML; Abdel-Wahab O; Taylor J; Steensma DP; Starczynowski DT; Sekeres MA; Sanz G; Sallman DA; Roboz GJ; Platzbecker U; Patnaik MM; Padron E; Odenike O; Nimer SD; Nazha A; Majeti R; Loghavi S; Little RF; List AF; Kim TK; Hourigan CS; Hasserjian RP; Halene S; Griffiths EA; Gore SD; Greenberg P; Figueroa ME; Fenaux P; Efficace F; DeZern AE; Daver NG; Churpek JE; Carraway HE; Buckstein R; Brunner AM; Boultwood J; Borate U; Bejar R; Bennett JM; Wei AH; Santini V; Savona MR; Zeidan AM
    Blood Rev; 2023 Nov; 62():101128. PubMed ID: 37704469
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.
    Versluis J; Saber W; Tsai HK; Gibson CJ; Dillon LW; Mishra A; McGuirk J; Maziarz RT; Westervelt P; Hegde P; Mukherjee D; Martens MJ; Logan B; Horowitz M; Hourigan CS; Nakamura R; Cutler C; Lindsley RC;
    J Clin Oncol; 2023 Oct; 41(28):4497-4510. PubMed ID: 37607457
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies.
    Gorak EJ; Otterstatter M; Al Baghdadi T; Gillis N; Foran JM; Liu JJ; Bejar R; Gore SD; Kroft SH; Harrington A; Saber W; Starczynowski D; Rollison DE; Zhang L; Moscinski L; Wilson S; Thompson J; Borchert C; Sherman S; Hebert D; Walker ME; Padron E; DeZern AE; Sekeres MA
    Blood Adv; 2023 Oct; 7(20):6120-6129. PubMed ID: 37552083
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum-based chemotherapy.
    Nakatsuru K; Tsubouchi K; Hirahata M; Nakashima T; Takahata Y; Okamatsu Y; Shiraishi Y; Okamoto I; Harada T
    Thorac Cancer; 2023 Aug; 14(22):2225-2228. PubMed ID: 37337950
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. GATA2 Deficiency: Predisposition to Myeloid Malignancy and Hematopoietic Cell Transplantation.
    Rajput RV; Arnold DE
    Curr Hematol Malig Rep; 2023 Aug; 18(4):89-97. PubMed ID: 37247092
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.
    Abel GA; Hebert D; Lee C; Rollison D; Gillis N; Komrokji R; Foran JM; Liu JJ; Al Baghdadi T; Deeg J; Gore S; Saber W; Wilson S; Otterstatter M; Thompson J; Borchert C; Padron E; DeZern A; Cella D; Sekeres MA
    Blood Adv; 2023 Jul; 7(14):3506-3515. PubMed ID: 37146263
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Structure-based virtual screening and molecular dynamics simulations for detecting novel candidates for allosteric inhibition of EGFRT790M.
    Çoban G
    J Biomol Struct Dyn; 2024; 42(2):571-597. PubMed ID: 37029759
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.
    DeZern AE; Goll JB; Lindsley RC; Bejar R; Wilson SH; Hebert D; Deeg J; Zhang L; Gore S; Al Baghdadi T; Maciejewski J; Liu J; Padron E; Komrojki R; Saber W; Abel G; Kroft SH; Harrington A; Grimes T; Reed H; Fulton RS; DiFronzo NL; Gillis N; Sekeres MA; Walter MJ
    Blood Adv; 2023 Jul; 7(14):3749-3759. PubMed ID: 36947201
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (mds): Proceedings from the 1
    Bewersdorf JP; Xie Z; Bejar R; Borate U; Boultwood J; Brunner AM; Buckstein R; Carraway HE; Churpek JE; Daver NG; Porta MGD; DeZern AE; Fenaux P; Figueroa ME; Gore SD; Griffiths EA; Halene S; Hasserjian RP; Hourigan CS; Kim TK; Komrokji R; Kuchroo VK; List AF; Loghavi S; Majeti R; Odenike O; Patnaik MM; Platzbecker U; Roboz GJ; Sallman DA; Santini V; Sanz G; Sekeres MA; Stahl M; Starczynowski DT; Steensma DP; Taylor J; Abdel-Wahab O; Xu ML; Savona MR; Wei AH; Zeidan AM
    Blood Rev; 2023 Jul; 60():101072. PubMed ID: 36934059
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Breast metastasis in high-grade endometrial stromal sarcoma (HG-ESS) with BCOR rearrangement: a case report of a novel metastatic site.
    Fong A; Offman S
    Diagn Pathol; 2023 Mar; 18(1):34. PubMed ID: 36864468
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
    Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.
    Eapen M; Brazauskas R; Williams DA; Walters MC; St Martin A; Jacobs BL; Antin JH; Bona K; Chaudhury S; Coleman-Cowger VH; DiFronzo NL; Esrick EB; Field JJ; Fitzhugh CD; Kanter J; Kapoor N; Kohn DB; Krishnamurti L; London WB; Pulsipher MA; Talib S; Thompson AA; Waller EK; Wun T; Horowitz MM
    J Clin Oncol; 2023 Apr; 41(12):2227-2237. PubMed ID: 36623245
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 8.